Minghao Tech Secures Tens of Millions of RMB in Series A Funding Led by Source Code Capital and Co-Invested by CITIC Healthcare Fund

Investment Circle (ID: pedaily2012) October 26th, by reporter, Minghao Technology, an innovative company focusing on medical vision technology, officially announcedCompleted tens of millions of RMB in Series A financing, led by the well-known investment institution Source Code Capital, with participation from CITIC Medical Fund.This round of financing has injected new vitality into the development of Minghao Technology, and will further promote the expansion of the company's self-innovated 5-degree precision fitting system and visual health solutions in both the medical and consumer markets, while accelerating its R&D and innovation in the fields of ophthalmology and vision science.

Since its establishment, Minghao Technology has consistently adhered to innovation in ophthalmology and visual science. Guided by customer vision needs, based on ophthalmic clinical medicine, and supported by the advanced precision manufacturing of optical lenses and state-of-the-art hardening coating processes, the company has gradually achieved remarkable success in the field of medical optometry. Its core products cover multiple areas, including medical refractive correction solutions, a 5-degree precision fitting system, high-quality optical lenses, and an optometric SAAS system for optical stores, earning significant recognition from numerous experts in the industry. To date, the company's 5-degree precision fitting system and optical lens products have been introduced into nearly 300 medical institutions across China, covering 16 provinces and autonomous regions.

Mr. Zhu Xiao, Founder, Chairman and CEO of Minghao Technology, stated:"We are honored to have gained the trust and recognition of top institutions in the healthcare field during our Series A funding round. This year, Minghao Technology's fully independent innovative product for slowing the progression of myopia in Chinese children and adolescents — the DianDian Sunshine 5-degree defocus lens — achieved encouraging results in clinical trials at Tongren Hospital. Its impressive myopia control rate of up to 70% has been widely acknowledged and reported by central media. Meanwhile, clinical research targeting different age groups, populations, and eye-use scenarios is being conducted in several well-known ophthalmic hospitals across China. Moving forward, we will continue to focus on developing vision health solutions for individuals with refractive errors worldwide. With the support of capital and the advantages of our technology platform, we will accelerate the R&D and productization of vision health technologies, bringing better visual solutions to consumers more quickly, fulfilling our mission — 'Discover a Clearer World.' Additionally, I would like to take this opportunity to welcome Professor Zhang Zuoming, who officially joins Minghao Technology as the Dean of Minghao Vision Research Institute and Chief Scientist. Professor Zhang Zuoming is the former Director of the Clinical Medicine Teaching and Research Section of the Department of Aerospace Medicine at Air Force Medical University; he is also an expert reviewer for projects such as the National Natural Science Foundation, the Ministry of Science and Technology's International Science and Technology Cooperation, and the Military Medical Achievement Awards. He has long been dedicated to teaching, research, and clinical work in ophthalmology and vision science. We believe that with Professor Zhang's expertise, we can better achieve Minghao Technology’s vision of becoming ‘the most trusted vision health company.’"

Mr. Kou Guan, Co-founder, Director and COO of Minghao Technology, stated:"Thanks to top-tier investment institutions for recognizing Minghao Technology's previous achievements and future potential. This round of financing will provide strong support for further market expansion of our existing precision fitting system and high-quality optical lens product lines. It will also help accelerate our research and product development in the field of visual science to meet more unmet vision health needs. Additionally, with the backing of this round of investment, we will officially enter the consumer market and launch two brand initiatives: 'Wangshu Vision' and 'Muyu Alliance.' 'Wangshu Vision' is positioned as a premium vision management service that applies all of Minghao Technology’s vision health research achievements to help consumers achieve the goal of 'Wangshu.' The 'Muyu Alliance' focuses on innovative cost-effective optical lens sales, with the mission of 'allowing Chinese people to wear good lenses.' Our domestically produced lenses, which rival international high-end product lines, will be offered at lower prices and with better services to benefit more people, establishing a 'New National Brand Light.'"

Dr. Zhang Yuhao, Executive Director of Source Code Capital, stated:Half of China's population is troubled by refractive errors of the eye, and the optometry industry is a large sector addressing people's needs for healthy vision. The preventive medicine nature of the industry places it between serious clinical settings and consumer scenarios, also posing challenges to establishing comprehensive product and industry standards. Minghao Technology is one of the few companies in the industry that we have seen to be consumer-demand-oriented, verifying the efficacy of its products with strict clinical standards. The company’s top-tier optical design and lens processing technology ensure the continuous development of high-quality clinical-grade optometry products. We are delighted to participate in this round of the company’s financing and look forward to its products benefiting a wide range of consumers soon.

CITIC Medical Fund stated:Eye health issues span all age groups and possess both medical and consumer attributes, making it a large market and a major track. Minghao Technology, guided by clinical needs, independently researches and innovates, developing products with significant clinical effects that have gained recognition from top ophthalmology experts in China. It is also one of the few companies in China with the capability for independent lens design and high-end precision manufacturing. Based on its own strengths and market demands, the company has created multiple brands and entered the vision consumption market, engaging in deep and innovative cooperation models with partners. We look forward to Minghao Technology, led by General Manager Zhu, benefiting more people with technology and becoming a trusted brand in visual health.